0000000001078342

AUTHOR

Ulrich Mey

showing 1 related works from this author

SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL…

2021

Cancer ResearchBortezomibbusiness.industryHematologyGeneral Medicinechemistry.chemical_compoundPhase i iiOncologychemistryIbrutinibCancer researchmedicineRefractory Mantle Cell Lymphomabusinessmedicine.drugHematological Oncology
researchProduct